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Abstract
Galectin-3 (Gal 3) is a glycan-binding protein that can be secreted by activated macrophages and mast cells at inflammation
sites and plays an important role in inflammatory diseases caused by Bacteria and their products, such as
lipopolysaccharides (LPS). Although it is well established that Gal 3 can interact with LPS, the pathophysiological
importance of LPS/Gal 3 interactions is not fully understood. Data presented herein demonstrate for the first time that the
interaction of Gal 3, either via its carbohydrate binding C-terminal domain or via its N-terminal part, with LPS from different
bacterial strains, enhances the LPS-mediated neutrophil activation in vitro. Gal 3 allowed low LPS concentrations (1 mg/mL
without serum, 1 ng/mL with serum) to upregulate CD11b expression and reactive oxygen species (ROS) generation on
human neutrophils in vitro and drastically enhanced the binding efficiency of LPS to the neutrophil surface. These effects
required LPS preincubation with Gal 3, before neutrophil stimulation and involved specific Gal 3/LPS interaction. A C-
terminal Gal-3 fragment, which retains the lectin domain but lacks the N-terminal part, was still able to bind both to
Escherichia coli LPS and to neutrophils, but had lost the ability to enhance neutrophil response to LPS. This result
emphasizes the importance of an N-terminus-mediated Gal 3 oligomerization induced by its interaction with LPS. Finally we
demonstrated that Balb/C mice were more susceptible to LPS-mediated shock when LPS was pretreated with Gal 3.
Altogether, these results suggest that multimeric interactions between Gal 3 oligomers and LPS potentiate its pro-
inflammatory effects on neutrophils.
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Introduction
Lipopolysaccharide (LPS) represents a major pathogen-associ-
ated molecular pattern (PAMP) from the outer membrane of
Gram-negative bacteria and is a potent immune activator closely
associated with many infectious and inflammatory diseases [1,2].
LPS recognition by polymorphonuclear neutrophils is one of the
first steps of innate immunity. Neutrophil activation by LPS
involves both the GPI-anchored molecule CD14 and the Toll-like
receptor-4 (TLR-4), with occasional participation of TLR-2
binding to lipoproteins. This activation results in neutrophil
degranulation and the activation of the oxidative burst [3]. Since
LPS is a powerful immune activator and may be fatal, the response
to LPS must be tightly regulated to maintain the immune response
at an appropriate level [4].
Gal 3 is a glycan-binding protein composed of a single
carbohydrate-recognition domain (CRD) [5–7] and an N-terminal
aggregation part responsible for its ability to form oligomers,
mainly pentamers [8–10]. It is widely distributed in tissues, and is
predominantly expressed by innate cells, including mast cells,
neutrophils and eosinophils [11]. Gal 3 is up-regulated during
inflammation/infection, and in vivo experiments using Gal 3-
deficient mice emphasized the critical role of this protein in
regulating inflammatory responses [12–15]. Several reports have
described the binding of Gal 3 to neutrophil surface and the
regulation of neutrophil functions by this protein [16–20].
However, the roles of Gal 3 remain unclear, since Gal 3 was
claimed either to favour neutrophil recruitment and activation
[12–15] or to down-regulate the LPS-induced inflammatory
responses [21]. One should point out that Gal 3 ubiquitous
subcellular distribution and its multiple extracellular and intracel-
lular biological effects render difficult the interpretation of
phenotypes observed with Gal 3
2/2 mice. Our aim was to clarify
the modulation by Gal 3 of LPS-mediated neutrophil activation
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26004and to investigate Gal 3 mechanisms of action. Data presented
herein demonstrate that exogenous Gal 3 lowers the activation
threshold of LPS-stimulated neutrophils by interacting directly
with LPS and by enhancing its ability to bind neutrophils.
Furthermore, the complex formed between LPS and Gal 3
modifies LPS structure, as deduced from fluorescence dequench-
ing and decreases mice resistance to the lethal effects of LPS.
Methods
Reagents
Hanks’ balanced salt solution with or without Ca
2+ and Mg
2+
(HBSS
2+ and HBSS
22) was purchased from Gibco (Paisley,
Scotland) and Polymorphprep from Nycomed (Oslo, Norway).
LPS from Klebsiella pneumonia, Escherichia coli O55:B5, Escherichia coli
fluorescein isothiocyanate (FITC)-conjugated LPS (FITC-LPS),
lactose, sucrose and formyl-Met-Leu-Phe-OH (fMLP) were
obtained from Sigma-Aldrich (St. Louis, MO), while LPS from
Salmonella Minnesota R7 was kindly donated by Dr. Catherine
Fitting (Pasteur Institute, Paris, FR). LPS preparations were
sonicated to prepare homogeneous solutions. Recombinant
human tumor necrosis factor alpha (TNF-a) and interleukin-8
(IL-8) were from PeproTech (Rocky Hill, NJ). Desalting Columns
were from Thermo Scientific (MA, USA), Detoxi-Gel
TM from
Pierce (Rockford, IL), anti-CD11b (FITC), -CD14 (FITC), -TLR4
(biotin) monoclonal antibodies, Streptavidin-PE and control
isotypes were from AbD Serotec (Du ¨sseldorf, Germany). The
polyclonal anti-Gal 3 antibody was produced as previously
described [10].
Galectin-3 preparation
Recombinant human Gal 3 was produced in Escherichia coli and
purified by as previously described [22]. The lectin was stored at
4uC in phosphate-buffered saline (PBS; pH 7.2) containing
150 mM lactose. Prior to use, lactose was removed by gel-
filtration chromatography on desalting columns and galectin 3 was
further purified by affinity chromatography on detoxi-gel beads to
eliminate contaminating LPS. The carboxyl-terminal domain
fragment of Gal 3 (Gal 3C) was prepared by digesting recombinant
lectin with collagenase as described [22]. Labeling of Gal 3 with
fluorescein isothiocyanate (FITC) was performed essentially as
previously described [23].
Neutrophil preparation
Neutrophils were prepared at room temperature from EDTA-
anticoagulated blood obtained at the French Blood Transfusion
Center E ´tablissement Franc ¸ais du Sang, with agreement for
studies on healthy volunteers. An initial centrifugation for 20
minutes at 120 g allowed to recover the platelet-rich plasma, which
was further centrifuged separately 10 minutes at 1000 g to remove
platelets. Blood cells were resuspended in the platelet-poor plasma
and neutrophils isolated by one step density-gradient centrifuga-
tion on Polymorphprep according to the manufacturer’s instruc-
tions. Residual erythrocytes were lysed in 0.2% NaCl for 1 minute
and the osmolarity of the medium then equilibrated by the
addition of an equal volume of 1.6% NaCl. Cells were washed in
PBS and resuspended in HBSS
2+ to a final concentration of 2610
6
cells/mL.
Neutrophil activation and flow cytometry
Neutrophils (5610
5) in 250 mlo fH B S S
2+, in 1% BSA-coated
tubes, were incubated for 20–45 minutes at 37uC with the indicated
molar concentrationofGal 3,LPS, 10
26 M fMLP,25 ng/mLIL-8,
10 ng/mL TNF-a or only HBSS
2+. Alternatively, neutrophils were
stimulated with a mixture containing Gal 3 and LPS. In this case,
Gal3andLPSwerepreincubated togetheratconcentrationsatleast
5 times higher than that used to stimulate neutrophils. After 20 min
at 37uC, the Gal 3/LPS mixture was diluted with HBSS
2+, adjusted
toindicated finalconcentrations and added tothe neutrophilpellets.
Resuspended neutrophils were then incubated at 37uC for 30 min.
For sugar inhibition assays, Gal 3 was pre-incubated with 20 mM
lactose or sucrose 15 minutes before use. To evaluate Gal 3 effects
on LPS-mediated neutrophil activation in the presence of the LPS
binding protein (LBP), 0,2% autologous serum was added to each
stimulus condition. For flow cytometry analysis, following the
activation, cells were washed with ice-cold PBS, 1% BSA, 0.1%
sodium azide (PBA buffer) and incubated for 20 minutes with heat-
aggregated goat IgG (1 mg/ml) to block Fcc receptors, at 4uC, the
low temperature and the presence of sodium azide preventing FccR
redistribution and activation. Cells were then treated at 4uC with
FITC-labeled anti-CD11b, anti-CD14, or anti-TLR4 mAbs or a
control FITC-labeled mouse IgG1 and analyzed by flow cytometry
on a Becton Dickinson FACSCalibur (Mountainview, CA).
Reactive oxygen species generation
PMN (1610
6/ml in HBSS
++) were incubated with the
fluorescent probe 29-79-dichlorofluorescin hydrodiacetate
DCFHDA (5 mM) (Sigma-Aldrich) in BSA-coated tubes at 37uC
for 30 min in the dark, with Gal 3 or LPS then with fMLP 10
26 M
for 7 minutes. The reaction was stopped with ice-cold PBS-azide
0.1%. After centrifugation, the oxydation-dependent fluorescence
of intracellular DCFHDA was measured by flow cytometry.
LPS and galectin-3 binding assay
A flow cytometric assay was developed to assess the effect of Gal
3 on the level of LPS binding on neutrophils. Cells (1610
5)i n
50 ml of HBSS
2+ were stimulated for 20 min at 37uC with FITC-
labeled Escherichia coli LPS (12.5 mg/mL), which had been
preincubated with different concentration of Gal 3 (from 0 to
8 mM) or with 4 mM of the truncated form of Gal 3 (Gal 3C). For
sugar inhibition assays, lactose or sucrose (12.5 mM) were added
to Gal 3, 15 minutes before use. For Gal 3 binding assay, non-
activated neutrophils were washed with iced-PBA buffer and
treated with 0.2 mM FITC-labeled Gal 3 in presence or absence of
10 mM lactose or sucrose. Following incubations, cells were
washed with PBS and the binding of Gal 3 or LPS was measured
by flow cytometry.
Competition assay
Each well in Microtiter plates with U-wells (Nunc, Roskilde,
Denmark) was treated with 1 mg of recombinant Gal 3 overnight
at 4uC. Plates were rinsed once with PBS, and the unbound
protein binding sites in the wells were blocked with 3% (w/v)
gelatin in PBS for 2 h at room temperature, followed by three PBS
rinses. To each well was added 0.2 mM biotin-labeled Gal 3 and
crescent concentration of unlabeled Gal 3 prepared in 1% gelatin,
in presence or absence of 5 mg/ml E.coli LPS. Plates were
incubated for 2 h at 37uC on an orbital shaker and washed with
PBS five times. Following incubation with streptavidin-peroxidase
for 1 h at 37uC, the Sigma FAST o-phenylenediamine dihydro-
chloride (OPD) substrate was used for development of peroxidase
reaction and the optical density was measured at 450 nm.
FITC-LPS gel filtration and fluorescence analysis
To study the effects of Gal 3 on LPS aggregate structure, 5 mgo f
FITC-LPS diluted in 200 mL PBS was incubated with 20 mMo f
Gal 3 or 2% human serum for 2 hours at 37uC. After incubation,
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column (Pahrmacia, Uppsala, Sweeden), running at a flow of
1 mL/min in PBS. FITC-LPS, Gal 3 or 2% serum alone were also
analyzed. Samples were collected into 500 mL fractions and
applied in a white 96-wells flat-bottom microtiter plate (Nunc,
Roskilde, Denmark), and thereafter the fluorescence was measured
in a Microplate Fluorescence reader FLX800 (Bio-Tek Instru-
ments, VT, USA). The excitation and emission wavelengths were
475 nm and 520 nm, respectively.
Mouse model of endotoxin-mediated mortality
Female Balb/C mice, in groups of five, were challenged with E.
coli LPS in three different doses (6.2, 12.5 and 25 mg/Kg) diluted
in 0.5 mL of PBS, by intraperitoneal (IP) inoculation. Mice were
observed for survival for 30 h. Using our established LD50 (Lethal
Dose, 50%) of LPS, the effect of Gal 3 on LPS-induced mortality
was assessed by preincubating Gal 3 (40 mM) and LPS (6.2 mg/
Kg) in 0.5 mL of PBS for 30 min before IP administration.
Control animals received PBS, Gal 3 only or LPS only. The Ethics
Committee on Animal Research of the University of Sao Paulo
approved all the procedures performed in the study described
here.
Statistical Analysis
The results are expressed as the mean 6SD of the indicated
number of animals or experiments. Statistical analysis was
performed using analysis of variance followed by the parametric
Tukey-Kramer test (Prism 5 GraphPad software, La Jolla, CA,
USA). Log rank (Mantel-Cox) test was used to compare the
survival rates between the study groups and generate the P value.
Differences were considered statistically significant when p#0.05.
Results
Recombinant galectin 3 exerts LPS-dependent and
LPS-independent effects on human neutrophils
We first analyzed the effects of recombinant Gal 3, isolated from
transfected E. coli as described [22], without (Gal 3 extract) and
with (detoxi) LPS elimination on detoxi-gel and incubated with
freshly isolated unprimed neutrophils. As shown in figure 1A, the
incubation with 0.2 mM Gal 3 extract resulted in neutrophil
activation, as measured by the increase of CD11b expression. This
effect was not observed with the same molar concentration of
endotoxin-free detoxigel-treated Gal 3 (detoxi-Gal 3). LPS
contamination of the Gal 3 extract preparation, as measured by
Limulus Amebocyte Lysate test, was less than 400 nanograms of
LPS per mg of Gal 3 (data not shown). We then pretreated the Gal
3 extract preparation with polymyxin B (PMX), to block the effect
of contaminating LPS. As shown in figure 1B, PMX prevented
CD11b up-regulation promoted by Gal 3 extract preparation or
by LPS. We then analyzed the effect of increasing doses of
endotoxin-free detoxigel-treated Gal 3 on unprimed neutrophils.
As shown in figure 1C, detoxi-Gal 3 concentrations up to 0.4 mM
had no significant effect on neutrophil activation state. One should
point out, however, that high molar concentrations ($0.8 mM)
resulted in a significant up-regulation of CD11b membrane
expression which, in this case, was PMX-insensitive.
The binding of Gal-3 to neutrophils surface was investigated,
using FITC-labeled detoxi Gal 3. Figure 1D shows that
concentrations as low as 0.2 mM detoxi-Gal 3 efficiently bound
to neutrophils, and that this binding was specifically inhibited by
lactose, thus involving Gal 3 carbohydrate recognition domain.
The concentrations of 0.2–0.4 mM Gal 3, allowing this binding of
Gal3 without modification of neutrophil CD11b levels, were
chosen to analyze the effect of Gal 3 on LPS-induced cell
activation.
Galectin 3 endows low doses of LPS with the ability to
activate neutrophils
The effects of Gal 3 on LPS-mediated neutrophil activation
were then investigated. LPS is known to lose most of its neutrophil
activating efficiency in the absence of serum LPS-binding protein
(LBP) and soluble CD14 [24] and concentrations as high as
10 mg/ml of LPS are required to activate neutrophils in the
absence of serum (data not shown). When unprimed human
neutrophils were incubated with suboptimal E. coli LPS concen-
tration (1 mg/ml) or with 0.4 mM detoxi-Gal 3, separately, these
stimuli induced little or no neutrophil activation (Figure 2A). By
contrast, a two- to three-fold increase of CD11b expression was
observed when neutrophils were treated with the same amount of
LPS that had been preincubated with Gal 3 (Figure 2A, 2B). We
also tested whether Gal 3 was able to enhance neutrophil oxidative
responses to LPS. LPS is not an efficient trigger of the oxidative
burst but it is known to prime PMN for an enhanced oxidative
response to fMLP [25]. Therefore, we first primed PMN with
either Gal 3, LPS or a pre-incubated mixture of Gal 3 and LPS, in
the presence of the fluorescent probe DCFHDA, and then further
activated PMN with fMLP. The results show that LPS
preincubation with Gal 3 increases the oxidant response of
PMN to LPS itself (DCFHDA indexes of 2.7760,2 and 260.09
with LPS/Gal3 and LPS alone, respectively) (Figure 2C).
Figure 1. Contaminating LPS interferes with the ability of Gal 3
to activate neutrophils. Freshly isolated neutrophils (2.0610
6/ml)
were incubated for 45 min at 37uC in HBSS
2+ in the presence of: A:
Recombinant Gal 3 preparation (0.2 mM), which had been depleted of
endotoxin (detoxi) or not (extract), by absorption on detoxigel (n=3). B:
0.2 mM of extract or endotoxin-depleted recombinant Gal 3, which had
been preincubated for 30 min at 37uC with polymyxin B (PMX, 40 mg/
ml) (n=3). C: Increasing molar concentrations of endotoxin-depleted
Gal 3 (n=3). After staining with a specific anti-CD11b mAb, cells were
analyzed by flow cytometry. D: Non-stimulated PMN (2.0610
6/mL) were
incubated with FITC-labeled Gal 3 (0.2 mM) for 30 min at 4uC, in the
presence or absence of 20 mM sucrose or lactose. The binding of FITC-
Gal 3 to neutrophils was analyzed by flow cytometry (n=3). Results are
expressed as mean fluorescence intensity (MFI). * p,0.05; **p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0026004.g001
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with the LPS/Gal3 mixture lead to up to 3 fold the oxidative
response to fMLP, as compared to the 1.8 fold increase observed
after priming by LPS alone (Figure 2C).
Finally, the effects of Gal 3 on neutrophil activation were also
tested with LPS in the presence of serum factors such as LBP and
CD14. In the presence of 0.2% normal human serum, as low as
1 ng/mL of LPS were able to activate neutrophils. Here again,
Gal 3 caused a further decrease in the LPS threshold since, in the
presence of serum, 0.1 ng/mL LPS preincubated with Gal 3
induced an increase of neutrophil CD11b expression similar to
1 ng/mL LPS alone (Figure 2D).
Galectin-3 effects on LPS-mediated activation require
galectin-3/LPS interactions
We initially concluded, as others [26,27], that the effect of Gal 3
on neutrophils required cell priming by LPS. However, surpris-
ingly, the enhancing effect of Gal 3 on LPS-mediated neutrophil
activation was not observed when neutrophils were primed with
1 mg/mL of LPS before the addition of Gal 3 (0.2 mM) or vice-
versa (Figure 3A). Indeed, LPS- or Gal 3-primed cells did not differ
significantly from cells treated with Gal 3 or LPS alone (Figure 3A).
Importantly, Gal 3 effects on neutrophil activation required a prior
interaction of Gal 3 with LPS, since only the pre-incubated Gal 3/
LPS was able to significantly increase neutrophil activation
(Figure 3A). In fact, we observed a dose-dependent up-regulation
of CD11b expression with increasing concentrations of LPS/Gal 3
during the preincubation step, although the final concentration in
contact with neutrophils was kept constant (0.2 mM Gal 3, 1 mg/
ml LPS) (Figure 3B). Moreover, a time-response curve for LPS/
Gal 3 preincubation revealed that the ability of Gal 3 to interact
with LPS and to induce CD11b up-regulation of expression was
very rapid in onset, reaching a plateau after 10 min of
preincubation (Figure 3C). These results further emphasize the
importance of a direct interaction of Gal 3 with LPS. The ability of
Gal 3 to enhance neutrophil activation was specifically observed
with LPS and not upon pre-incubation with other stimuli such as
fMLP, TNF-a or IL-8 (Figure 3D).
Galectin-3/LPS-mediated neutrophil activation relies on
N- or C-terminal parts of Gal 3, according to LPS bacterial
strains
In order to investigate the Gal 3 parts involved in the observed
effects, we analyzed LPS from different strains known to interact
either with gal 3 lectin domain (Klebsiella pneumonia), with gal 3 N-
terminal part (Salmonella minnesota R7 (Rd mutant) or with both N-
terminal and lectin parts (E. coli) [21,28]. As shown in Figure 3E,
Gal 3 endows all three strains of LPS with an enhanced ability to
up-regulate neutrophil CD11b (black bars). This effect was
inhibited by lactose in the case of E. coli LPS and K. pneumonia,
but not in the case of S. minnesota R7 LPS, confirming that the
lectin domain is not involved in Gal 3 interaction with this latter
LPS. Altogether, these results indicate that Gal 3 effects on LPS-
mediated neutrophil activation require an interaction of LPS with
either the glycan-binding or the N-terminal part of Gal 3.
Gal-3 strikingly enhances the interaction of LPS with
neutrophils
To test whether the Gal 3-mediated increase in LPS binding
might be caused by an up-regulation of LPS receptors on
neutrophils, we analyzed the expression of CD14 and TLR4. As
shown in figure 4, there was no significant change in TLR4 (A)
and CD14 (B) expressions after neutrophil stimulation with the
Gal 3/LPS complex. We then hypothesized that Gal 3 enhances
the effects of LPS by increasing its binding to neutrophil surface.
We thus preincubated FITC-labeled E. coli LPS with increasing
concentrations of Gal 3 for 30 min before adding it to neutrophils.
One should point out that low concentrations of FITC-LPS (1 mg/
mL) preincubated with 0.4 mM of Gal 3, in the absence of serum,
did not result in a level of fluorescence intensity detected by flow
cytometry. Therefore, we increased proportionally the doses of
FITC-LPS and Gal 3 and found that the dose of 12.5 mg/mL LPS
allowed the detection of cell-bound LPS. Preincubation of this
amount of LPS with increasing concentrations of Gal 3 showed a
significant increase of LPS binding to neutrophils for a Gal 3/LPS
proportion (4 mM Gal 3 per 10 mg LPS) similar to that required for
neutrophil activation. As expected, previous treatment of Gal 3
with lactose (12.5 mM) specifically inhibited the Gal 3-induced
binding of LPS to neutrophils (Figure 4D). Gal 3/LPS interactions
thus strikingly enhance the binding of LPS to the cell surface.
LPS induces N-terminal part-dependent Gal 3
oligomerization
Since the binding of FITC-LPS to neutrophils is more
pronounced as the concentration of Gal 3 reaches a threshold
concentration (2 mM, Figure 4C), we next tested the ability of LPS
to trigger galectin-3 self-association. Biotin-labeled Gal 3, without
Figure 2. Gal 3 increases the ability of LPS to activate
neutrophils and induces oxidative responses. PMNs (2.0610
6/
ml) were incubated for 45 min at 37uC with E. coli LPS (1 mg/mL) and
Gal 3 (0.4 mM), which had been preincubated separately or together for
30 min at 37uC; after labeling with a specific anti-CD11b mAb, cells
were analyzed by flow cytometry. A: Representative histrogram of
neutrophil CD11b expression. B: Bar graph representation of data
obtained from 5 experiments (mean 6 SD). C: PMNs were incubated at
37uC for 30 min with DCFHDA and either Gal 3 (5 mg/ml), LPS (1 mg/ml)
or a mixture of Gal 3 and LPS pre-incubated for 20 min at 37uC. Then,
PMN were further activated or not with fMLP 10
26 M for 7 minutes. The
reaction was stopped by the addition of ice-cold PBS-azide 0.1% and
the oxydation-dependent fluorescence of intracellular DCFHDA was
measured as described in Methods. The results are given as DCFHDA
index, i.e. the mean fluorescence intensity MFI of each sample/MFI of
resting PMN (n=3). D: Increasing concentrations of LPS (0.1 to 1000 ng/
ml), in 0.2% autologous serum, were preincubated or not with Gal 3
(0.4 mM) and then added to PMNs. CD11b expression was measured as
above after a 45-min incubation and expressed as mean MFI 6 SD
(n=3). *p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0026004.g002
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in the presence of increasing amounts of unlabeled Gal 3. As
shown in figure 5A, the unlabeled Gal 3 did not compete with the
biotin-galectin 3, since the amount of biotin-galectin 3 binding was
not decreased, but on the contrary slightly enhanced in the
presence of a 10 time excess of unlabeled Gal 3. This suggests the
occurrence of Gal 3 oligomerization, which was enhanced in the
presence of LPS (Figure 5A).
In order to test the hypothesis that LPS induces Gal 3
oligomerization via the N-terminal part of the molecule, we used
the C-terminal fragment Gal 3C, generated by collagenase
digestion of Gal 3, which lacks the N-terminal part but still
possesses the carbohydrate-binding activity. First, Gal 3C was
shown to be able to bind to neutrophils, as detected with a
polyclonal anti-Gal 3C antibody (Figure 5B). This binding was
saturable, reaching a plateau at about 1.2 mM Gal 3C, unlike that
observed with FITC-labeled full-length Gal 3 (Figure 5C). This
non-saturable binding illustrates the ability of the full-length Gal 3,
at high concentration, to form multimers, via its N-terminal part,
on neutrophils, while Gal 3C had lost this ability. Similarly,
contrasting with the full-length Gal 3, Gal 3C was unable to
increase the binding of FITC-LPS to neutrophils (Figure 5D) and
to enhance the LPS-mediated neutrophil activation, as shown in
Figure 5E, where LPS was preincubated with Gal 3C concentra-
tions up to four times greater than those used for full-length Gal 3.
These results emphasize the importance of N-terminal part-
mediated Gal 3 oligomerization in its ability to enhance LPS
binding to and activation of neutrophils.
Gal 3/LPS interaction leads to an increase in the
fluorescence of FITC-LPS in a similar way as serum LBP
protein
The fact that Gal 3/LPS interaction induces greater-than 20-
fold increase in FITC-LPS binding to neutrophils but only a three-
fold increase in LPS-mediated CD11b up-regulation raised the
possibility that galectin-3 might interfere with the intramolecular
self-quenching of fluorescein. It has long been known that the
fluorescence of FITC-LPS aggregates is self quenched but should
increase when the aggregates dissociate [29] or the spacing
between FITC-LPS molecules within aggregates increase [30],
because of dequenching. Therefore, FITC-LPS, preincubated or
not with Gal 3 or with serum LPB, was analyzed by gel filtration
followed by fluorescence detection. Figure 6 represents the analysis
of the main peak of FITC-LPS recovered in the void volume and
clearly demonstrates that the presence of Gal 3 enhances three
times the FITC-LPS fluorescence. Similar results were obtained
Figure 3. Gal 3 specifically enhances LPS-mediated neutrophil activation and requires a direct interaction with LPS for its effect. A:
PMNs were primed for 30 min at 37uC with Gal 3 (0.2 mM) or E. coli LPS (1 mg/mL) and then stimulated with LPS (1 mg/mL) or Gal 3 (0.2 mM),
respectively. Alternatively, Gal 3 (1 mM) and LPS (5 mg/mL) were preincubated together for 30 min at 37uC and then diluted to 0.2 mM (Gal 3) and
1 mg/mL (LPS) to be used to stimulate PMNs (n=2). B: Effect of increasing LPS and Gal 3 concentrations in the pre-incubation mixture. Increasing
concentrations of Gal 3 (0.2 mMt o2 5mM) and LPS (1 mg/mL to 125 mg/mL) were preincubated together for 30 min at 37uC. They were then diluted in
HBSS
2+ to the final Gal 3 2 0.2 mM and LPS – 1 mg/ml concentrations and added to PMN for a 45-min incubation at 37uC. C: Time-response curve of
LPS and Gal 3 preincubation. Gal 3 (7 mM) and LPS (35 mg/mL) were preincubated together for 0–30 min, as indicated, at 37uC and then diluted to
0.2 mM (Gal 3) and 1 mg/mL (LPS) to be used to stimulate PMNs for a 45-min incubation at 37uC (representative from 2 independent experiments). D:
PMNs were stimulated with LPS (1 mg/ml), fMLP (10
26 M), TNF-a (10 ng/ml) or IL-8 (25 ng/ml), which had all been preincubated without (black) or
with Gal 3 (0.4 mM, grey) for 30 min at 37uC. Neutrophil CD11b expression was measured as in figure 1 (n=5). E: Gal 3 effect on neutrophil activation
by LPS from various strains of bacteria. Gal 3 (1 mM) was preincubated with 10 mg/ml LPS from E. coli, K. pneumonia or S. minnesota R7 for 30 min at
37uC, in presence or absence of 10 mM lactose (lac). Then, each mixture was diluted to 0.2 mM (Gal 3) and 1 mg/mL (LPS) concentrations and used to
stimulate PMNs (2610
6/mL) for 45 min at 37uC, and analyzed for CD11b expression as above. Results are expressed as mean fluorescence intensity
(MFI) (n=3). * p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0026004.g003
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known to promote LPS disaggregation [31]. This result suggests
that Gal 3/LPS interaction is able to modify the LPS aggregate
structure, which may account, at least in part, for its potentiating
effect on LPS-induced neutrophil activation.
Exogenous Gal 3 increases mortality to endotoxin shock
induced by LPS
Endotoxic shock is the most severe form of LPS-mediated
inflammatory disease, which is mainly mediated by an uncon-
trolled neutrophil activation [32–36]. So far we have shown that
Gal 3 lowers the activation threshold of LPS-stimulated neutro-
phils in vitro. We, thus, further explored Gal 3 effect in an in vivo
sepsis model. First, in order to determine a suitable concentration
of LPS for inducing endotoxemia, mice were challenged with
different doses of LPS (Figure 7A). All mice receiving 25 mg/Kg
LPS died, while those receiving LPS at 6.2 mg/Kg exhibited 50%
survival during a 30-hour period. Therefore, we assessed the
influence of Gal 3 on endotoxin-mediated mortality by measuring
survival of mice challenged with LPS (6.2 mg/Kg) preincubated
with 500 mL of Gal 3 (40 mM) for 15 minutes before the challenge.
As shown in figure 7B, all mice receiving PBS or Gal 3 alone
survived, while 60% of mice receiving LPS at 6.2 mg/Kg survived
up to 30 h past challenge, as expected. Interestingly, all mice
challenged with LPS pre-incubated with Gal 3 died within 30 h
after challenge. This result suggests that exogenous Gal 3 can
enhance the effect of LPS both in vitro and in vivo.
Discussion
The major conclusion of this study is that galectin-3 decreases
ten times the LPS concentration threshold for neutrophil
activation. This may be important in inflammation sites where
Gal 3, secreted in situ by macrophages or mast cells, may render
neutrophils particularly sensitive to LPS.
Various reports have described Gal 3 in vitro pro-inflamma-
tory effects on neutrophils, which required cell priming with
fMLP [17] or TNF-a [37]. Similarly, Almkvist and colleagues
previously stated that neutrophils had to encounter bacterial
LPS first, in order to be activated by galectin-3, on the basis of
results showing that Gal 3 triggered responses of neutrophils pre-
incubatedwith 10 mg/ml LPS [27]. In our experimental settings,
which used LPS concentrations as low as 1 mg/ml in the absence
of serum or 1 ng/ml with serum, Gal 3 had no effect on LPS-
pretreated neutrophils. However, Gal 3 pre-incubation with
LPS enhanced the ability of these low LPS concentrations to
activate naı ¨ve, unprimed neutrophils, as shown by the upregula-
tion of CD11b expression. Gal 3 specifically potentiated
neutrophil activation by LPS and had no effect on cell activation
by other agonists such as fMLP, TNF-a or IL-8. Indeed, our
results emphasize the importance of specific Gal 3/LPS
interactions, as shown by a concentration dependent effect of
Gal 3 preincubation with LPS on the resulting neutrophil
activation (Figure 3B). The required concentrations for the
galectin 3/LPS pre-incubation step are high but are most
probably reached when Gal 3 secreting macrophages get in
contact with LPS-releasing bacteria in inflamed tissues. More-
over, the final Gal 3 concentrations used to stimulate neutrophils
w er es i m i l a ro rl o w ert ot h os eu s e di np r e v i o u s l yr e p or te di nv i t r o
data on Gal 3 effects [16,17,19,20,26,27].
Our results confirm that some of the in vitro effects of
recombinant E. coli-derived Gal 3 preparations are due to an
LPS contamination and are inhibited by polymyxin B [38]. The
detoxified LPS-free Gal 3 efficiently bound to neutrophils, via its
Figure 4. Gal 3 enhances LPS binding to the neutrophil surface. A and B: PMNs (2610
6/mL) were stimulated for 45 min with Gal 3 (0.4 mM)
and E. coli LPS (1 mg/ml), preincubated as in figure 3. TLR4 (A) and CD14 (B) expressions were determined by flow cytometry. The results are
expressed as mean fluorescence intensity (MFI) (n=3). C: FITC-labeled E. coli LPS (12.5 mg/mL) was preincubated with increasing molar
concentrations of Gal 3 (from 0.25 to 8 mM) and then added to PMNs (10610
6/mL) for additional 20 min incubation at 37uC with (n=3) D. Gal 3 was
treated with 12.5 mM lactose or sucrose for 15 min before being incubated with FITC-LPS (12.5 mg/mL) and added to PMNs (10610
6/mL). The
binding of FITC-LPS was determined by flow cytometry and expressed as mean fluorescence intensity (MFI).
doi:10.1371/journal.pone.0026004.g004
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neutrophils at concentrations lower than 0.8 mM.
Two independent LPS binding sites on galectin-3 have been
demonstrated so far. One is the carbohydrate binding site in the
C-terminal domain of Galectin-3, which confers binding to b-
galactoside-containing LPS from K. pneumonia. In contrast, S.
minnesota LPS is devoid of b-galactosides, but can bind to a site
within the N-terminal domain of galectin-3 through its Lipid A
part, known to be essential for LPS-mediated bioactivity [28]. In
addition, E. coli LPS binds to galectin-3 both through Lipid A and
b-galactoside-containing polysaccharide chains [21]. The analysis
of LPS from different strains of bacteria showed that Gal 3
interaction with E. coli, K. pneumonia and S. minnesota LPS enhanced
LPS-mediated neutrophil activation. Accordingly, blocking the
lectin domain with lactose inhibited the effect of Gal 3 on E. coli
and K. pneumonia LPS but not its effect on S. minnesota LPS, further
demonstrating that, no matter what domain is involved, the
interaction between LPS and Gal 3 is essential to the enhanced
neutrophil activation mediated by LPS.
The effect of Gal 3 was further investigated with Gal 3 C-
terminal fragment Gal 3C, which retains its ability to bind, via its
lectin site, to neutrophil membrane (Figure 5B). Although this
Figure 5. LPS induces oligomerization of Gal 3. A: A 96-well microplate was coated with 1 mg of recombinant Gal 3 per well. After blocking with
gelatin 3%, 0.2 mM biotin-labeled Gal 3 ([b]Gal 3) and the indicated concentrations of unlabeled Gal 3 were added to each well in the presence (solid
squares) or absence (open squares) of 5 mg/mL E. coli LPS. The signal was generated by neutravidin-HRP using OPD as a substrate. B and C: PMNs
(2610
6/mL) were incubated for 30 min at 4uC with increasing concentrations of truncated Galectin-3 (Gal 3C), lacking the N-terminal part (B), or
increasing concentration of full-length Galectin-3 (Gal 3) (C). After washing, a specific polyclonal goat anti-Gal 3C (B) or goat anti-Gal 3 (C) and an
FITC-labeled secondary anti-goat IgG antibody were used to detect Gal 3C on neutrophils by flow cytometry (n=2). D: PMNs (10610
6/mL) were
treated for 20 min at 37uC with FITC-LPS (12.5 mg/mL) preincubated with Gal 3 (8 mM) or with Gal 3C (8 mM). The binding of FITC-LPS was evaluated
by flow cytometry as in figure 4. E: PMNs (2610
6/mL) were treated for 45 min at 37uC with the indicated concentrations of full-length Gal 3 (Gal 3) or
Gal 3C, preincubated or not with E. coli LPS (1 mg/mL), and analyzed for CD11b expression by flow cytometry. ***p,0.001.
doi:10.1371/journal.pone.0026004.g005
Figure 6. Gal 3/LPS interaction enhances the fluorescence of
FITC-LPS. FITC-labeled E. coli LPS (10 mg/ml) was incubated with 4 mM
Gal 3 or 2% serum for 2 hours, and then applied to a gel filtration
column (Superdex TM 75 HR 10/30 column). FITC-LPS alone or Gal 3
alone were also analyzed. 0.5 ml fractions of FITC-LPS 6 Gal 3 or 62%
serum were collected and further analyzed on a fluorescence
microplate reader. The excitation and emission wavelengths were at
475 nm and 520 nm, respectively. Data represents the fluorescence of
the main peak of FITC-LPS recovered in the void volume. ** p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0026004.g006
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enhance the binding of LPS to neutrophils (Figure 5D) and the
resulting cell activation (Figure 5E). These results emphasize the
importance of Gal 3 oligomerization, via its N-terminal part, in the
LPS-enhancing effect.
Gal 3 oligomerization could also account for the striking
increase of LPS binding to neutrophils, when LPS was pre-
incubated with Gal 3, in spite of a constant number of LPS
receptors, TLR4 and CD14.
It is well established that, in the absence of ligands, galectin-3 is
monomeric, but it oligomerizes upon binding to synthetic
multivalent or cell surface glycans, through self-association of N-
terminal parts [8,22,39]. Efficient oligomerization, in the presence
of ligands such as IgE, was shown to require a minimal galectin-3
concentration of 1.0 mM [22]. Similarly, galectin-3 oligomeriza-
tion was reported to occur on the surface of neutrophils [18] but
with 2 mM Gal 3 concentration, i.e. 10 times that of our
experimental setting, which is probably not sufficient to allow
the formation of oligomers on the cell surface. The fact that the
enhancement of LPS-mediated neutrophil activation was only
achieved if galectin-3 had been preincubated, at concentrations
equal or higher than 1 mM, with LPS, strongly suggests that LPS
itself induces galectin-3 oligomerization during this preincubation
step. This was confirmed by the analysis of the formation of
galectin 3 oligomers on galectin 3-coated plates, which was
significantly enhanced by the presence of LPS (Figure 5A). To our
knowledge, this is the first observation of galectin-3 oligomeriza-
tion promoted by LPS.
Our results raise the question as to how galectin-3 oligomer-
ization could lower the activation threshold of neutrophils to LPS.
One possibility is that each galectin-3 oligomer, binding several
LPS molecules, cross-links LPS receptors such as CD14 and TLR4
on the cell surface, thereby increasing their cell activating
efficiency, as schematized in figure 8. Moreover, simultaneous
interaction of galectin-3 carbohydrate recognition domain with
glycans on LPS receptors such as CD14 [31,40,41] could further
enhance the binding of LPS to the cell surface. Another
hypothesis, which does not exclude the former one, is that galectin
3 dissociates LPS aggregates, as has been observed with LPS-
binding protein (LBP). Indeed, LPS, in aqueous suspension, forms
aggregates with low cell activating efficiency, which are disrupted
by LPS-binding protein (LBP) [42]. This accelerates LPS binding
to CD14 and enhances the resulting TLR-4-mediated cell
signaling. We observed that the fluorescence of FITC-LPS was
enhanced upon incubation with Galectin 3 (Figure 6), which
indicates that galectin-3 somehow interferes with LPS aggregate
structure. However, at this point we are not able to assert that Gal
3 promotes LPS disaggregation in a way similar to LBP or that it
just interferes with the space between FITC molecules, thus
promoting dequenching [30]. Gal 3 putative dissociation of LPS
aggregates (Figure 8) could account for the ability of low
concentrations of LPS to stimulate neutrophils, when pre-
incubated with Gal 3, even in the absence of serum LBP. An
intriguing observation is galectin-3 enhancement of cell activation
induced by Salmonella minesota LPS, which only binds to galectin-3
via its N-terminal part. This indicates that galectin-3 oligomeri-
zation may be triggered by the engagement of the N-terminal part
with ligands, an observation not described so far, opening a new
avenue in the study of galectin-3 functions.
When LPS reaches the systemic circulation, it induces a massive
release of proinflammatory cytokines, that cause the pathophysio-
logical state known as endotoxic shock [43]. Our results showing an
increased mortality of mice challenged with LPS preincubated with
galectin-3 do not proove that the increased mortality is due to the
direct activation of neutrophils by LPS/Gal3 complexes. It could
be due to LPS/Gal3 interactions with resident cells such as
macrophages, resulting in increased secretion of TNF-a, IL-8 and
other cytokines and ultimately in neutrophil hyperactivation. These
results, however, definitely argue in favour of an amplifying role for
galectin-3inLPS-induced cellularresponses.This contrasts with the
data ofLiand colleagues[21],who demonstratedthatgal3
2/2mice
were more susceptible to endotoxin shock and observed dramat-
ically increased galectin-3 serum levels in wild-type mice 4 h after
LPS challenge. The reason for this discrepancy may be searched in
the analogy between Gal 3 and LBP behavior towards LPS. Indeed,
in spite of the enhancing effect of LBP on LPS signalling at low
concentration, LBP inhibits this signalling, when present in high
concentration, by shuttling LPS to the serum lipoproteins and by
formation of LPS aggregates [44,45]. It has, therefore, been
suggested that LBP may serve as an inhibitor of the excessive
response to LPS, which would explain its higher levels found in the
serum of septic patients [46]. It is tempting to speculate that, in the
experimental setting used by Li and colleagues [21], the systemic
galectin-3 concentration found after LPS challenge (,300 ng/mL)
would not be sufficient to enhance LPS-induced activation and
therefore may exert an inhibitory role. The same authors showed
that the in vitro preincubation of LPS with galectin-3 reduced the
responsiveness of bone marrow-derived macrophages (BMMs) to
LPS. However, BMMs may react differently than neutrophils and,
more importantly, they used galectin-3 doses as low as 5–20 nM,
which, in our system, would be without enhancing effect.
In conclusion, regarding the physiological function played by
LPS-galectin-3 interactions during infections caused by gram-
negative bacteria, we propose that galectin-3 could serve as a
sensor to detect small amounts of LPS and allow it to efficiently
Figure 7. Gal 3/LPS interaction decreases mice resistance to the
lethality of LPS. A: Groups of 5 Balb/C mice were challenged with
PBS, 6.2, 12.5 or 25 mg/kg of E. coli LPS by intraperitoneal (ip) injection.
B: Mice (5 per group) were challenged with 500 ml of PBS, Gal 3 (40 mM),
6.2 mg/kg LPS or with a mixture of LPS (6.2 mg/kg) and Gal 3 (40 mM)
preincubated for 15 min. The mortality rate was monitored regularly
and represented as percentage of survival. *p,0.05.
doi:10.1371/journal.pone.0026004.g007
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galectin-3-deficient mice (gal3
2/2) developed a delayed inflam-
matory response during the early phase (6–24 hrs) of Rhodococcus
equii infection [47] argues in favour of a role for galectin-3 as a
pathogen danger signal in this model. Moreover, galectin-3 could
be an innate immune sensor with a broader specificity than LPS.
Indeed, galectin-3 has been shown to bind mycolic acid (MA), the
major constituents of Mycobacterium tuberculosis cell envelop
[48]. Interestingly, these authors also demonstrated that MA
interferes with an initial formation of galectin-3 oligomers on a
laminin substratum, although galectin-3 oligomerization on
immobilized MA was not assayed. The ability of galectin-3 to
bind two hydrophobic ligands such as MA and Lipid A, as in
Salmonella minnesota R7 LPS, opens the possibility that galectin-3
may also interact with Lipoteichoic acid (LTA), a major
constituent of the wall cell of gram-positive bacteria. Interestingly,
LPS-binding protein also interacts with LTA from gram-positive
bacteria and promotes its interaction with CD14 [49]. The
possible interaction between galectin-3 and LTA, or other product
from gram-positive bacteria, warrants further investigation.
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